The global asthma drugs market size is calculated at USD 26.49 billion in 2025 and is forecasted to reach around USD 41.04 billion by 2034, accelerating at a CAGR of 5.01% from 2025 to 2034. The North America market size surpassed USD 12.59 billion in 2024 and is expanding at a CAGR of 5.02% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Asthma Drugs Market Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Asthma Drugs Market Market Revenue and Volume Forecast, by Medication
8.1.1. Quick Relief Medications
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Long-term Control Medications
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Others
8.1.3.1. Market Revenue and Volume Forecast
9.1. Asthma Drugs Market Market Revenue and Volume Forecast, by Mode of Administration
9.1.1. Tablets and Capsules
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Liquids
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Inhalers
9.1.3.1. Market Revenue and Volume Forecast
9.1.4. Injections
9.1.4.1. Market Revenue and Volume Forecast
10.1. Asthma Drugs Market Market Revenue and Volume Forecast, by Organization Type
10.1.1. Public
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Private
10.1.2.1. Market Revenue and Volume Forecast
11.1. Asthma Drugs Market Market Revenue and Volume Forecast, by Application
11.1.1. Pediatric
11.1.1.1. Market Revenue and Volume Forecast
11.1.2. Adults
11.1.2.1. Market Revenue and Volume Forecast
11.1.3. Adolescent
11.1.3.1. Market Revenue and Volume Forecast
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Medication
12.1.2. Market Revenue and Volume Forecast, by Mode of Administration
12.1.3. Market Revenue and Volume Forecast, by Organization Type
12.1.4. Market Revenue and Volume Forecast, by Application
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Medication
12.1.5.2. Market Revenue and Volume Forecast, by Mode of Administration
12.1.5.3. Market Revenue and Volume Forecast, by Organization Type
12.1.5.4. Market Revenue and Volume Forecast, by Application
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Medication
12.1.6.2. Market Revenue and Volume Forecast, by Mode of Administration
12.1.6.3. Market Revenue and Volume Forecast, by Organization Type
12.1.6.4. Market Revenue and Volume Forecast, by Application
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Medication
12.2.2. Market Revenue and Volume Forecast, by Mode of Administration
12.2.3. Market Revenue and Volume Forecast, by Organization Type
12.2.4. Market Revenue and Volume Forecast, by Application
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Medication
12.2.5.2. Market Revenue and Volume Forecast, by Mode of Administration
12.2.5.3. Market Revenue and Volume Forecast, by Organization Type
12.2.5.4. Market Revenue and Volume Forecast, by Application
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Medication
12.2.6.2. Market Revenue and Volume Forecast, by Mode of Administration
12.2.6.3. Market Revenue and Volume Forecast, by Organization Type
12.2.6.4. Market Revenue and Volume Forecast, by Application
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Medication
12.2.7.2. Market Revenue and Volume Forecast, by Mode of Administration
12.2.7.3. Market Revenue and Volume Forecast, by Organization Type
12.2.7.4. Market Revenue and Volume Forecast, by Application
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Medication
12.2.8.2. Market Revenue and Volume Forecast, by Mode of Administration
12.2.8.3. Market Revenue and Volume Forecast, by Organization Type
12.2.8.4. Market Revenue and Volume Forecast, by Application
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Medication
12.3.2. Market Revenue and Volume Forecast, by Mode of Administration
12.3.3. Market Revenue and Volume Forecast, by Organization Type
12.3.4. Market Revenue and Volume Forecast, by Application
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Medication
12.3.5.2. Market Revenue and Volume Forecast, by Mode of Administration
12.3.5.3. Market Revenue and Volume Forecast, by Organization Type
12.3.5.4. Market Revenue and Volume Forecast, by Application
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Medication
12.3.6.2. Market Revenue and Volume Forecast, by Mode of Administration
12.3.6.3. Market Revenue and Volume Forecast, by Organization Type
12.3.6.4. Market Revenue and Volume Forecast, by Application
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Medication
12.3.7.2. Market Revenue and Volume Forecast, by Mode of Administration
12.3.7.3. Market Revenue and Volume Forecast, by Organization Type
12.3.7.4. Market Revenue and Volume Forecast, by Application
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Medication
12.3.8.2. Market Revenue and Volume Forecast, by Mode of Administration
12.3.8.3. Market Revenue and Volume Forecast, by Organization Type
12.3.8.4. Market Revenue and Volume Forecast, by Application
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Medication
12.4.2. Market Revenue and Volume Forecast, by Mode of Administration
12.4.3. Market Revenue and Volume Forecast, by Organization Type
12.4.4. Market Revenue and Volume Forecast, by Application
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Medication
12.4.5.2. Market Revenue and Volume Forecast, by Mode of Administration
12.4.5.3. Market Revenue and Volume Forecast, by Organization Type
12.4.5.4. Market Revenue and Volume Forecast, by Application
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Medication
12.4.6.2. Market Revenue and Volume Forecast, by Mode of Administration
12.4.6.3. Market Revenue and Volume Forecast, by Organization Type
12.4.6.4. Market Revenue and Volume Forecast, by Application
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Medication
12.4.7.2. Market Revenue and Volume Forecast, by Mode of Administration
12.4.7.3. Market Revenue and Volume Forecast, by Organization Type
12.4.7.4. Market Revenue and Volume Forecast, by Application
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Medication
12.4.8.2. Market Revenue and Volume Forecast, by Mode of Administration
12.4.8.3. Market Revenue and Volume Forecast, by Organization Type
12.4.8.4. Market Revenue and Volume Forecast, by Application
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Medication
12.5.2. Market Revenue and Volume Forecast, by Mode of Administration
12.5.3. Market Revenue and Volume Forecast, by Organization Type
12.5.4. Market Revenue and Volume Forecast, by Application
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Medication
12.5.5.2. Market Revenue and Volume Forecast, by Mode of Administration
12.5.5.3. Market Revenue and Volume Forecast, by Organization Type
12.5.5.4. Market Revenue and Volume Forecast, by Application
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Medication
12.5.6.2. Market Revenue and Volume Forecast, by Mode of Administration
12.5.6.3. Market Revenue and Volume Forecast, by Organization Type
12.5.6.4. Market Revenue and Volume Forecast, by Application
13.1. GlaxoSmithKline
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Pfizer
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Vectura Group
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Boehringer Ingelheim
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Roche
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Novartis
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Merck
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. AstraZeneca
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Teva Pharmaceutical
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample